Blood Podcast How I Treat Series on the 25th anniversary of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Jan 22, 2026
Yves Chalandon, transplant physician in Geneva, discusses when stem cell transplant is needed and timing. Elisabetta Abruzzese, hematologist in Rome, covers CML care during pregnancy and multidisciplinary planning. Simona Soverini, clinical researcher in Bologna, focuses on resistance testing and mutation-driven decisions. Neil Shah, academic hematologist in San Francisco, talks about personalizing TKI choice and dosing strategies.
AI Snips
Chapters
Transcript
Episode notes
Transcript Type And Cost Affect Practical Choices
- Transcript type matters because some variants are inherently resistant to asciminib.
- Drug cost and generic availability also strongly influence real-world choices.
Rule Out Adherence And Test Mutations First
- Always assess adherence and drug interactions first when responses are suboptimal.
- Test for BCR-ABL mutations and additional cytogenetic abnormalities before switching TKIs.
Manage CML In Pregnancy By Trimester
- For CML diagnosed in pregnancy, tailor therapy to disease severity and trimester.
- Use interferon in first trimester for cytoreduction and consider imatinib or nilotinib after 16 weeks if needed.